Peptomyc Appoints Selwyn Ho to its Board of Directors

March 22, 2024

Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting the MYC oncoprotein for cancer treatment, today announced the appointment of Dr. Selwyn Ho, MB, BS, to its Board of Directors.


Read more